(Entertainment-NewsWire.com, August 26, 2019 ) Meticulous Research® in its latest publication on Allergic Diagnostics market titled “Allergy Diagnostics Market by Product (Assay Kits, Immunoassay & Elisa Analyzers, Luminometers, Services), Allergens (Food, Inhaled, Drug), Tests (In Vivo, In Vitro), End Users (Hospital, Diagnostic Laboratory, Research) – Global Forecast to 2024”
Allergy is a type of reaction of immune systems and can appear in many forms and cause many symptoms such as sneezing, respiratory symptoms such as asthma or hay fever, itching, skin rashes, or generalized reaction such as anaphylaxis. The burden of allergic diseases is growing across the globe. According to European Academy of Allergy and Clinical Immunology 2016, allergy is the most common chronic disease in Europe. Around 20% of patients with allergies struggle daily with the fear of a possible asthma attack, anaphylactic shock, or even death from an allergic reaction. According to American College of Allergy, Asthma, and Immunology (ACAAI), allergies are the 6th leading cause of chronic illness in the U.S and annual cost of allergies exceeds $18 billion.
Key Topics Covered in This Report:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Market Insights
5 Global Allergy Diagnostics Market, by Product & Service
Increasing incidence and economic burden of allergic diseases, growing environmental pollution, and improving reimbursement scenario for allergy diagnosis in developed countries are key factors driving the growth of this market. Limited awareness about allergy diseases especially in developing countries and high capital investment for small laboratories may hinder the growth of this market.
Based on product & service, the global allergy diagnostics market is segmented into assay kits, instruments, and services. Assay kits accounted for the largest share of this market in 2018. The large share of this segment is mainly attributed to widespread availability, lower cost and significant consumption of assay kits in allergy testing.
Based on end user, the global allergy diagnostics market is segmented into diagnostic laboratories, hospital-based laboratories, academic and research institutes, and other end users. Diagnostic laboratories are expected to dominate the global allergy diagnostics market, by end user in 2018. The large share and high growth of this segment is mainly attributed to increasing number of diagnostic centers, rising investment and improving infrastructure of diagnostic labs, and greater preference and convenience to conduct these tests at these centers.
Future Outlook
Percutaneous skin prick tests (SPT) have been considered the preferred method for allergy diagnostics. However, although molecular-based allergy diagnostics (MA-Dx) is currently reserved for situations of complex allergies and polysensitization, it is likely that in the future, MA-Dx will play a bigger role in the evaluation of allergic patients.
Biomérieux SA (France), Hitachi Chemical Co., Ltd. (Japan), Hob Biotech Group Suzhou Co., Ltd. (China), Hycor Biomedical, Inc. (U.S.), Lincoln Diagnostics, Inc. (U.S.), Omega Diagnostics Group PLC (U.K.), R-Biopharm AG (Germany), Stallergenes Greer (U.K.), Siemens AG (Germany), Thermo Fisher Scientific Inc. (U.S.) are some of the key players operating in this market. These players are adopting various organic and inorganic growth strategies in order to strengthen their presence and customer base.
